Who climbs the tryptophan ladder? On the structure and function of the WSXWS motif in cytokine receptors and thrombospondin repeats

Cytokine and Growth Factor Reviews

Volumn 25, Issue 3, 2014, Pages 337-341

  Olsen, Johan G ^a   Kragelund, Birthe B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cytokine type I receptor; Glycosaminoglycans; Thrombospondin type 1 repeat; WS motif; WSXWS

Indexed keywords

CYTOKINE RECEPTOR; GROWTH HORMONE RECEPTOR; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 3 RECEPTOR; PROTEOGLYCAN; THROMBOSPONDIN; TRYPTOPHAN;

BINDING AFFINITY; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL STRUCTURE; CRYSTAL STRUCTURE; EXTRACELLULAR MATRIX; GLYCOSYLATION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; SHORT SURVEY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; PROTEIN MOTIF; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

AMINO ACID MOTIFS; ANIMALS; EXTRACELLULAR MATRIX; HUMANS; RECEPTORS, CYTOKINE; REPETITIVE SEQUENCES, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN;

EID: 84902077833     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.04.007     Document Type: Short Survey

References (45)

1. Guo N.H., Krutzsch H.C., Negre E., Zabrenetzky V.S., Roberts D.D. Heparin-binding peptides from the type I repeats of thrombospondin, structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis. J Biol Chem 1992, 267(27):19349-19355.
2. Jorge A.A., Souza S.C., Arnhold I.J., Mendonca B.B. The first homozygous mutation (S226I) in the highly-conserved WSXWS-like motif of the GH receptor causing Laron syndrome: supression of GH secretion by GnRH analogue therapy not restored by dihydrotestosterone administration. Clin Endocrinol (Oxf) 2004, 60(1):36-40.
3. Hilton D.J., Watowich S.S., Katz L., Lodish H.F. Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor. J Biol Chem 1996, 271(9):4699-4708.
4. Dagil R., Knudsen M.J., Olsen J.G., O'Shea C., Franzmann M., Goffin V., et al. The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor. Structure 2012, 20(2):270-282.
5. Song G., Koksal A.C., Lu C., Springer T.A. Shape change in the receptor for gliding motility in Plasmodium sporozoites. Proc Natl Acad Sci U S A 2012, 109(52):21420-21425.
6. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol 2011, 12(11).
7. Jordan S.N., Olson S., Canman J.C. Cytokinesis: thinking outside the cell. Curr Biol 2011, 21(3):R119-R121.
8. Feinstein Y., Klar A. The neuronal class 2 TSR proteins F-spondin and Mindin: a small family with divergent biological activities. Int J Biochem Cell Biol 2004, 36(6):975-980.
9. Giacobini P., Prevot V. Semaphorins in the development, homeostasis and disease of hormone systems. Semin Cell Develop Biol 2013, 24(3):190-198.
10. Tanaka K., Arao T., Tamura D., Aomatsu K., Furuta K., Matsumoto K., et al. SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer. PLoS One 2012, 7(1).
11. Sun Z., Reid K.B.M., Perkins S.J. The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling. J Mol Biol 2004, 343(5):1327-1343.
12. Buettner F.F., Ashikov A., Tiemann B., Lehle L., Bakker H. C. elegans DPY-19 is a C-mannosyltransferase glycosylating thrombospondin repeats. Mol Cell 2013.
13. Hofsteenge J., Huwiler K.G., Macek B., Hess D., Lawler J., Mosher D.F., et al. C-mannosylation and O-fucosylation of the thrombospondin type 1 module. J Biol Chem 2001, 276(9):6485-6498.
14. Tan K., Duquette M., Liu J.H., Dong Y., Zhang R., Joachimiak A., et al. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J Cell Biol 2002, 159(2):373-382.
15. Aleshin A.E., Schraufstatter I.U., Stec B., Bankston L.A., Liddington R.C., DiScipio R.G. Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC). J Biol Chem 2012, 287(13):10210-10222.
16. Hadders M.A., Bubeck D., Roversi P., Hakobyan S., Forneris F., Morgan B.P., et al. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 2012, 1(3):200-207.
17. Lovelace L.L., Cooper C.L., Sodetz J.M., Lebioda L. Structure of human C8 protein provides mechanistic insight into membrane pore formation by complement. J Biol Chem 2011, 286(20):17585-17592.
18. Furmanek A., Hess D., Rogniaux H., Hofsteenge J. The WSAWS motif is C-hexosylated in a soluble form of the erythropoietin receptor. Biochemistry 2003, 42(28):8452-8458.
19. Doucey M.A., Hess D., Blommers M.J., Hofsteenge J. Recombinant human interleukin-12 is the second example of a C-mannosylated protein. Glycobiology 1999, 9(5):435-441.
20. Hamming O.J., Kang L., Svensson A., Karlsen J.L., Rahbek-Nielsen H., Paludan S.R., et al. Crystal structure of interleukin-21 receptor (IL-21R) bound to IL-21 reveals that sugar chain interacting with WSXWS motif is integral part of IL-21R. J Biol Chem 2012, 287(12):9454-9460.
21. Conway-Campbell B.L., Brooks A.J., Robinson P., Perani M., Waters M.J. The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation. Mol Endocrinol 2008, 22(9):2190-2202.
22. Uberti B., Dentelli P., Rosso A., Defilippi P., Brizzi M.F. Inhibition of beta1 integrin and IL-3Rbeta common subunit interaction hinders tumour angiogenesis. Oncogene 2010, 29(50):6581-6590.
23. Edwards G.M., Wilford F.H., Liu X., Hennighausen L., Djiane J., Streuli.C.H. Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. J Biol Chem 1998, 273(16):9495-9500.
24. Streuli C.H., Edwards G.M., Delcommenne M., Whitelaw C.B., Burdon T.G., Schindler C., et al. Stat5 as a target for regulation by extracellular matrix. J Biol Chem 1995, 270(37):21639-21644.
25. Xu R., Spencer V.A., Bissell M.J. Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors. J Biol Chem 2007, 282(20):14992-14999.
26. Tossavainen H., Pihlajamaa T., Huttunen T.K., Raulo E., Rauvala H., Permi P., Kilpelainen I. The layered fold of the TSR domain of P. falciparum TRAP contains a heparin binding site. Protein Sci 2006, 15(7):1760-1768.
27. Holt G.D., Pangburn M.K., Ginsburg V. Properdin binds to sulfatide [Gal(3-SO4)beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates. J Biol Chem 1990, 265(5):2852-2855.
28. Zaferani A., Vives R.R., van der Pol P., Hakvoort J.J., Navis G.J., van Goor H., et al. Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease. J Biol Chem 2011, 286(7):5359-5367.
29. Qiu H., Jiang J.L., Liu M., Huang X., Ding S.J., Wang L. Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling. Mol Cell Proteomics 2013, 12(8):2160-2173.
30. Kirn-Safran C., Farach-Carson M.C., Carson D.D. Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci 2009, 66(21):3421-3434.
31. Kirn-Safran C.B., D'Souza S.S., Carson D.D. Heparan sulfate proteoglycans and their binding proteins in embryo implantation and placentation. Semin Cell Dev Biol 2008, 19(2):187-193.
32. Gallagher J.T. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001, 108(3):357-361.
33. Sasisekharan R., Venkataraman G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 2000, 4(6):626-631.
34. Farach-Carson M.C., Carson D.D. Perlecan-a multifunctional extracellular proteoglycan scaffold. Glycobiology 2007, 17(9):897-905.
35. Choi Y., Chung H., Jung H., Couchman J.R., Oh E.S. Syndecans as cell surface receptors: unique structure equates with functional diversity. Matrix Biol 2011, 30(2):93-99.
36. Heremans A., De Cock B., Cassiman J.J., Van den Berghe H., David G. The core protein of the matrix-associated heparan sulfate proteoglycan binds to fibronectin. J Biol Chem 1990, 265(15):8716-8724.
37. Brandhorst T.T., Roy R., Wuthrich M., Nanjappa S., Filutowicz H., Galles K., et al. Structure and function of a fungal adhesin that binds heparin and mimics thrombospondin-1 by blocking T cell activation and effector function. PLoS Pathog 2013, 9(7):pe1003464.
38. Hileman R.E., Fromm J.R., Weiler J.M., Linhardt R.J. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 1998, 20(2):156-167.
39. Oakley F.D., Smith R.L., Engelhardt J.F. Lipid rafts and caveolin-1 coordinate interleukin-1 beta (IL-1 beta)-dependent activation of NF kappa B by controlling endocytosis of Nox2 and IL-1 beta receptor 1 from the plasma membrane. J Biol Chem 2009, 284(48):33255-33264.
40. Yang N., Huang Y., Jiang J., Frank S.J. Caveolar and lipid raft localization of the growth hormone receptor and its signaling elements-impact on growth hormone signaling. J Biol Chem 2004, 279(20):20898-20905.
41. Giancotti F.G., Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Ann Rev Cell Develop Biol 2003, 19:173-206.
42. Lei J.T., Martinez-Moczygemba M. Separate endocytic pathways regulate IL-5 receptor internalization and signaling. J Leukoc Biol 2008, 84(2):499-509.
43. Marmor M.D., Julius M. Role for lipid rafts in regulating interleukin-2 receptor signaling. Blood 2001, 98(5):1489-1497.
44. Barcus C.E., Keely P.J., Eliceiri K.W., Schuler L.A. Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. J Biol Chem 2013, 288(18):12722-12732.
45. Adage T., Piccinini A.M., Falsone A., Trinker M., Robinson J., Gesslbauer B., et al. Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br J Pharmacol 2012, 167(6):1195-1205.